ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
October 02 2008 - 7:00AM
PR Newswire (US)
Webcast Presentation Scheduled for Monday, October 6, 2008 at 3:00
p.m. EDT BROOMFIELD, Colo., Oct. 2 /PRNewswire/ -- ARCA biopharma,
Inc., a biopharmaceutical company developing genetically-targeted
therapies for heart failure and other cardiovascular diseases,
today announced that Richard Brewer, the company's president and
chief executive officer, and Dr. Michael Bristow, M.D., ARCA's
chairman and chief science and medical officer, will present at the
Third Annual JMP Securities Healthcare Focus Conference on Monday,
October 6, 2008, at 3:00 p.m. EDT in New York City. ARCA biopharma
and Nuvelo, Inc. (NASDAQ:NUVO) announced on September 25, 2008 that
they have entered into a definitive merger agreement, expected to
create a cardiovascular-focused, late-stage biotechnology company.
The presentation will discuss the assets of both companies,
including ARCA's lead product Gencaro(TM) (bucindolol
hydrochloride) a near-term commercial opportunity, as well as
Nuvelo's mid-stage pipeline asset, novel short-acting anticoagulant
NU172, to drive long-term growth. ARCA recently announced that the
FDA has accepted a New Drug Application for Gencaro. The
presentation will also discuss the structure and strategic plan of
the combined company, pending the closing of the merger. A live
audio webcast of the presentation will be available online via the
ARCA biopharma website at http://www.arcabiopharma.com/, the
Investor Relations portion of Nuvelo's website at
http://www.nuvelo.com/ or http://www.wsw.com/webcast/jmp7/nuvo/.
About ARCA biopharma ARCA biopharma, Inc. is a privately held
company focused on developing and commercializing genetically
targeted therapies for heart failure and other cardiovascular
diseases. The Company's lead product candidate, Gencaro(TM)
(bucindolol hydrochloride), is an investigational pharmacologically
unique beta-blocker and mild vasodilator being developed for heart
failure and other indications. ARCA has identified common genetic
variations that predict individual patient response to Gencaro. The
NDA for Gencaro, including the proposed brand name, is under review
by FDA. The companion genetic test for Gencaro is in development by
ARCA's partner, Laboratory Corporation of America. For more
information please visit http://www.arcabiopharma.com/. About
Nuvelo Nuvelo, Inc. is dedicated to improving the lives of patients
through the discovery, development and commercialization of novel
drugs for acute cardiovascular disease, cancer and other
debilitating medical conditions. Nuvelo's development pipeline
includes NU172, a direct thrombin inhibitor which has completed
Phase 1 development for use as a potential short-acting
anticoagulant during medical or surgical procedures; and NU206, a
Wnt pathway modulator in Phase 1 development for the potential
treatment of chemotherapy/radiation therapy-induced mucositis and
inflammatory bowel disease. In addition, Nuvelo is pursuing
research programs in leukemia and lymphoma therapeutic antibodies
and Wnt signaling pathway therapeutics to further expand its
pipeline and create additional partnering and licensing
opportunities. Information about Nuvelo is available at our website
at http://www.nuvelo.com/ or by phoning 650-517-8000.
Forward-looking statements This press release contains
"forward-looking statements" which include, without limitation,
statements regarding the completion of the proposed merger
transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc.,
the transaction's anticipated benefits, timing, progress and
anticipated completion of the combined company's clinical stage and
research programs, which statements are hereby identified as
"forward-looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Such statements are based on our management's current expectations
and involve risks and uncertainties. Actual results and performance
could differ materially from those projected in the forward-
looking statements as a result of many factors, including, without
limitation, failure of Nuvelo or ARCA's stockholders to approve the
merger, the ability to complete the transaction contemplated by
this communication in a timely fashion, the risk that Nuvelo's and
ARCA's business operations will not be integrated successfully; the
combined company's inability to further identify, develop and
achieve commercial success for products and technologies; the risk
that the combined company's financial resources will be
insufficient to meet the combined company's business objectives;
uncertainties relating to drug discovery and the regulatory
approval process; clinical development processes; enrollment rates
for patients in our clinical trials; changes in relationships with
strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements;
and the impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in Nuvelo's filings with the SEC, including without limitation
Nuvelo's quarterly report on Form 10-Q for the quarter ended June
30, 2008 and subsequent filings. We disclaim any intent or
obligation to update these forward-looking statements. Additional
Information and Where to Find It Nuvelo intends to file a
registration statement on Form S-4, and a related proxy
statement/prospectus, in connection with the merger. Investors and
security holders are urged to read the registration statement on
Form S-4 and the related proxy statement/prospectus when they
become available because they will contain important information
about the merger transaction. Investors and security holders may
obtain free copies of these documents (when they are available) and
other documents filed with the SEC at the SEC's website at
http://www.sec.gov/. In addition, investors and security holders
may obtain free copies of the documents filed with the SEC by
contacting Nuvelo Investor Relations at the email address: or by
phone at 650-517-8000. In addition to the registration statement
and related proxy statement/prospectus, Nuvelo files annual,
quarterly and special reports, proxy statements and other
information with the SEC. You may read and copy any reports,
statements or other information filed by Nuvelo, Inc. at the SEC
public reference room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for more information.
Please call the SEC at 1-800-SEC-0330 for further information on
the public reference room. Nuvelo, Inc.'s filings with the SEC are
also available to the public from commercial document-retrieval
services and at SEC's website at http://www.sec.gov/, and from
Investor Relations at Nuvelo as described above. This communication
shall not constitute an offer to sell or the solicitation of an
offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. Nuvelo, ARCA and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from the stockholders of Nuvelo in connection with the
merger transaction. Information regarding the special interests of
these directors and executive officers in the merger transaction
will be included in the proxy statement/prospectus of described
above. Additional information regarding the directors and executive
officers of Nuvelo is also included in Nuvelo's proxy statement for
its 2008 Annual Meeting of Stockholders which was filed with the
SEC on April 23, 2008 and its Annual Report on Form 10-K for the
year ended December 31, 2007, which was filed with the SEC on March
12, 2008. These documents are available as described above.
DATASOURCE: ARCA biopharma, Inc. CONTACT: Rebekah Brooks,
+1-312-646-6293, , of Invigorate, for ARCA biopharma, Inc. Web
site: http://www.arcabiopharma.com/ http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jul 2023 to Jul 2024